Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 230

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 230
---
:-------------------------------------|-----------:|:--|:--------|-----------:|:--|:--------|-----------:|:--|:--------|-----------:|
| Net loss                                             | ​ | $                                    |       -161 | ​ | $       |       -167 | ​ | $       |       -859 | ​ | $       |       -895 |
| Denominator                                          | ​ |                                      |            | ​ |         |            | ​ |         |            | ​ |         |            |
| Basic and diluted weighted average units outstanding | ​ |                                      | 95,555,554 | ​ |         | 16,666,666 | ​ |         | 95,555,554 | ​ |         | 16,666,666 |
| Basic and diluted net loss per member unit           | ​ | $                                    |      -0.00 | ​ | $       |      -0.01 | ​ | $       |      -0.01 | ​ | $       |      -0.05 |

Recently Adopted Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” that addresses requests for improved income tax disclosures from investors that use the

F-26

financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these unaudited condensed financial statements. Recently Issued Accounting Pronouncements On November 4, 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expensesto improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disag